• Skip to primary navigation
  • Skip to main content
  • Skip to primary sidebar
  • Skip to footer

MassDevice

The Medical Device Business Journal — Medical Device News & Articles | MassDevice

  • Latest News
    • Cardiovascular
    • Orthopedics
  • Wall Street Beat
    • Funding Roundup
    • Mergers & Acquisitions
  • Podcasts
    • MPR: Breakthrough Products Series
  • Resources
    • About MassDevice
    • Newsletter Signup
    • Job Board
    • Leadership in Medtech
    • Manufacturer Search
    • MedTech 100 Index
    • Videos
    • Whitepapers
  • DeviceTalks Tuesdays
    • DeviceTalks
  • Coronavirus: Live updates

Takeda Pharmaceuticals

Takeda, BioSurfaces collab on GI drug-delivery devices

July 25, 2017 By Sarah Faulkner

Takeda Pharmaceutical (TYO:4502) and BioSurfaces said today that the two companies inked a deal to develop novel medical devices intended to treat patients with gastrointestinal diseases. The deal brings together Takeda’s experience in the gastroenterology space and BioSurfaces’ method of developing nanomaterials from FDA-approved polymers for medical implants and drug-delivery devices. Financial terms of the deal were not […]

Filed Under: Drug-Device Combinations, Pharmaceutical, Research & Development, Wall Street Beat Tagged With: biosurfaces, Takeda Pharmaceuticals

Aptar Pharma’s nasal spray compliance device wins EMA nod

May 15, 2017 By Sarah Faulkner

Aptar Pharma said today that the European Medicines Agency approved its electronic nasal lockout device, e-Lockout. The device is the 1st and only fully-integrated electronic nasal drug delivery device to be approved by a European regulatory authority, according to the company. The e-Lockout device is a part of a multi-year development deal with Takeda Pharmaceuticals […]

Filed Under: Drug-Device Combinations, Pain Management, Pharmaceutical, Regulatory/Compliance Tagged With: aptarpharma, Takeda Pharmaceuticals

Takeda, Cognition Kit launch pilot of wearable cognitive software for assessing MDD

February 23, 2017 By Fink Densford

Takeda (TYO:4502) said today it is collaborating with Cambridge Cognition Holdings and Ctrl Group Ltd joint Cognition Kit to pilot study of a specially designed Apple (NSDQ:AAPL) Watch application to assess cognitive function in patients with major depressive disorder. The Cognition Kit is designed to assess cognitive symptoms in patients with MDD and move patient care […]

Filed Under: Business/Financial News, Neurological, Patient Monitoring Tagged With: Cambridge Cognition Holdings, Cognition Kit, Takeda Pharmaceuticals

TiGenix, Takeda highlight data for cell therapy in patients with Chron’s disease

February 17, 2017 By Sarah Faulkner

Takeda (TYO:4502) and TiGenix (EBR:TIG) today touted long-term data from its phase III Admire-CD trial evaluating its suspension of allogenic expanded adipose-derived stem cells, Cx601, in patients with Chron’s disease. The study showed that Cx601 maintained long-term remission of treatment refractory complex perianal fistulas over 52 weeks. The randomized, phase III trial compared Cx601 to […]

Filed Under: Clinical Trials, Stem Cells, Wall Street Beat Tagged With: Takeda Pharmaceuticals, TiGenix

TiGenix IPO raises $36m

December 15, 2016 By Sarah Faulkner

TiGenix (EBR:TIG) said today that it raised $36 million in an initial public offering from the sale of 2.3 million American depository shares, representing 46 million ordinary shares, at $15.50 apiece. The biopharmaceutical company plans to list on the NASDAQ exchange under the “TIG” symbol by Dec. 15. It is listed on the Euronext Brussels under the same symbol. […]

Filed Under: Drug-Device Combinations, Initial Public Offering (IPO), Pharmaceutical, Stem Cells, Wall Street Beat Tagged With: Takeda Pharmaceuticals, TiGenix

Takeda looks to wearables for IBD patients

September 8, 2016 By Sarah Faulkner

Takeda Pharmaceuticals (TYO:4502) yesterday launched a wearable watch pilot program to help people suffering with inflammatory bowel disease track their symptoms. Takeda said they will roll out the program, iBData, with 100 patients tracking their daily symptoms and lifestyle factors. Then, the data is collected into a report that is shared with the patient’s doctor, […]

Filed Under: Digital Health, Patient Monitoring Tagged With: Takeda Pharmaceuticals

Toshiba Medical Systems enters the race for Takeda’s chemicals subsidiary

August 19, 2016 By Brad Perriello

Toshiba Medical Systems, the medical device business Toshiba (TYO:6502) is selling to Canon (NYSE:CAJ) for $6.5 billion, reportedly entered the race to acquire a chemicals subsidiary of Takeda Pharmaceutical (TYO:4502). The Nikkei business daily reported today that Takeda is looking to sell its 70% stake in Osaka-based Wako Pure Chemicals Industries, with the 1st round of bidding closing August 16. Toshiba Medical is competing […]

Filed Under: Mergers & Acquisitions, Wall Street Beat Tagged With: Canon, Fujifilm, Hitachi Medical, Takeda Pharmaceuticals, Toshiba, Wako Pure Chemicals

  • « Go to Previous Page
  • Go to page 1
  • Go to page 2

Primary Sidebar

MEDTECH 100 INDEX

Medtech 100 logo
Market Summary > Current Price
The MedTech 100 is a financial index calculated using the BIG100 companies covered in Medical Design and Outsourcing.
Need Medtech news in a minute?
We Deliver!

MassDevice Enewsletters get you caught up on all the mission critical news you need in med tech. Sign up today.

Tweets by @MassDevice
MDO ad

Footer

MASSDEVICE MEDICAL NETWORK

DeviceTalks
Drug Delivery Business News
Medical Design & Outsourcing
Medical Tubing + Extrusion

MASSDEVICE

Subscribe to MassDevice
Advertise with us
About
Contact us

Add us on Facebook Follow us on Twitter Connect with us on LinkedIn Follow us on YouTube

Copyright © 2021 · WTWH Media LLC and its licensors. All rights reserved.
The material on this site may not be reproduced, distributed, transmitted, cached or otherwise used, except with the prior written permission of WTWH Media.

Advertise | Privacy Policy | RSS